News & Events CTI To Present at 11th Annual Brains 4 Brain International Workshop

CTI To Present at 11th Annual Brains 4 Brain International Workshop

March 30, 2017

CTI To Present at 11th Annual Brains 4 Brain International Workshop

FOR IMMEDIATE RELEASE [Cincinnati, OH ~ March 30, 2017]

CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization will present at the 11th Annual Brains 4 Brain (B4B) International Workshop on March 31st in Frankfurt, Germany. Dr. Achim Nutzenberger, Medical Director, will present the abstract, “Bridging the Gap Between Translational Research and Clinical Studies in Rare Neurological Disorders – Scientific Challenges and Study Design Considerations including Enrichment Strategies and Adaptive Design Options”.

Since 2007, B4B has organized annual international scientific workshops that aim to enable information exchange among clinicians, scientists and experts specialized in these disorders, with pharmaceutical companies and family associations.

"I am very excited to participate in this important international workshop," according to Dr. Nutzenberger. "CTI has extensive experience in rare neurological disorders,  and we look forward to sharing our experience with those at this meeting."

Dr. Nutzenberger has significant experience in the clinical development of pharmaceuticals and medical devices, including marketing, sales, and pharmacovigilance, as well as over two decades of additional therapeutic experience in urology, ophthalmology, nephrology, and transplantation. Previously, he served as Head of the NephroCare Coordination Clinical Research Organization within Fresenius Medical Care, where he played a leading role in managing a network of more than 800 clinics, more than 90,000 patients and more than 20,000 employees in Europe, the Middle East, Africa, and Latin America. In this role, he was also responsible for all clinical research activities and for the set-up of medical research services, database evaluations, and feasibilities for third party pharmaceutical and device industry clients. Dr. Nutzenberger completed his medical studies at the Universities of Bochum and Ulm, Germany, Harvard University, and the Technical University of Munich, Germany.

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit

About Brains 4 Brain (B4B)

B4B is an international task force composed of outstanding scientists and clinicians who are leaders in the neurological field. Together with biotech companies, they aim to facilitate joint efforts to improve the understanding of rare genetic diseases affecting and seriously damaging the brain, in particular in children. The Foundation is particularly promoting and coordinating research projects focused on the search of biomarkers for the understanding of pathophysiological process of neurometabolic disorders. Among the more than 500 types of hereditary metabolic diseases known today, the Foundation mainly focuses its attention on a group of about 40 genetically and biochemically very well characterised diseases, called Lysosomal Storage Disorders (LSDs). For more information visit

Media Contact

Allison Schroeder - CTI | 513.598.9290 |

Subscribe to our mailing list

* indicates required